Latest News and Press Releases

Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022 DUBLIN, Ireland, and Boston MA, September 7, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage...

Amryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin...

DUBLIN, Ireland, and Boston MA, July 21, 2022, Amryt (Nasdaq: AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for...

Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome DUBLIN, Ireland, and Boston MA, July 14, 2022, Amryt (Nasdaq: AMYT), a...

Amryt Presents New Analyses from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022 - Key highlights include efficacy of Oleogel-S10 (birch triterpenes) on accelerated wound healing, data on...

DUBLIN, Ireland, and Boston MA, July 1, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare...

Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer DUBLIN, Ireland, and Boston MA, June 27, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company...

Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA Filsuvez® recently approved by the European Commission for the treatment of EB DUBLIN, Ireland, and Boston MA, June 24,...

European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB Filsuvez® will be the first and only approved treatment for EB Patients DUBLIN, Ireland, and Boston MA,...

Amryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022 Data from the MPOWERED OLE and first presentation of open-label extension (OLE) data from 2nd...